Brian J. Brille - 17 Sep 2026 Form 4 Insider Report for Caris Life Sciences, Inc. (CAI)

Reporting relationship: Vice Chairman and Executive Vice President, Director
Issuer ticker: CAI
Reported as of: 17 Sep 2026
Net transaction value: -$12,132,080
SEC form: 4
Accepted by SEC: 17 Sep 2026, 18:08:31 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

Brian J. Brille filed Form 4 for Caris Life Sciences, Inc. (CAI) on 17 Sep 2026.

Key facts

This page summarizes Brian J. Brille's Form 4 filing for Caris Life Sciences, Inc. (CAI).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Sep 2026, 18:08.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: -$12,132,080.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002071959 Primary reporting owner

Brille Brian J

Relationship: Vice Chairman and Executive Vice President, Director
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 17 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Options Exercise

Transaction value
Shares: +400,000
Change %: +174%
Price: $2.44^*
Shares after: 630,303
Date: 17 Sep 2026
Ownership: Direct

CAI transaction

Common Stock

Sale

Transaction value: $12,132,080
Shares: -400,000
Change %: -63%
Price: $30.33
Shares after: 230,303
Date: 17 Sep 2026
Ownership: Direct
Footnotes: F1

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 500,000
Date: 17 Sep 2026
Ownership: By Trust
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAI transaction Derivative

Stock Option

Options Exercise

Transaction value
Shares: -400,000
Change %: -20%
Price: $0.000000^*
Shares after: 1,600,000
Date: 17 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $2.44
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Footnote F3

By a family trust, with shares previously held in multiple family trusts consolidated into a single trust.

Footnote F4

The stock option is fully vested and exercisable.

SEC remarks

Vice Chairman and Executive Vice President